利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.035 秒)

    Regulated nucleic acids in pathogenesis of Alzheimer's Disease
    1.
    发明申请
    Regulated nucleic acids in pathogenesis of Alzheimer's Disease 审中-公开
    调节核酸在阿尔茨海默氏病的发病机制中

    公开(公告)号：US20050176030A1

    公开(公告)日：2005-08-11

    申请号：US10973858

    申请日：2004-10-25

    申请人： Li Gan ,  Mirella Gonzalez-Zulueta ,  Shiming Ye ,  Roman Urfer ,  Karoly Nikolich

    发明人： Li Gan ,  Mirella Gonzalez-Zulueta ,  Shiming Ye ,  Roman Urfer ,  Karoly Nikolich

    IPC分类号： C12Q1/68 ,  G01N33/53 ,  G01N33/567

    CPC分类号： C12Q1/6883 ,  C12Q2600/142 ,  C12Q2600/158

    摘要： This invention provides a method for detecting a neurodegenerative disorder or susceptibility to a neurodegenerative disorder in a subject. This invention also provides a method of developing a modulator of an Alzheimer's Disease-associated gene or protein. Also included in the present invention is a method reducing toxic Aβ peptide production by a eukaryotic cell, a method of ameliorating neurotoxicity of Aβ peptide. The present invention further embodies compositions such as Alzheimer's Disease-associated genes, the polypeptides encoded therefrom, gene delivery vehicles, host cells and kits comprising the Alzheimer's Disease-associated genes and/or polypeptides.

    摘要翻译： 本发明提供了一种用于检测受试者中神经变性疾病或对神经变性疾病的易感性的方法。 本发明还提供了开发阿尔茨海默病相关基因或蛋白质的调节剂的方法。 本发明还包括减少真核细胞产生毒性的Aβ肽的方法，改善Abeta肽的神经毒性的方法。 本发明进一步体现了诸如阿尔茨海默病相关基因，由其编码的多肽，基因递送载体，宿主细胞和包含阿尔茨海默病相关基因和/或多肽的试剂盒的组合物。

    Sigma ligands for neuronal regeneration and functional recovery
    3.
    发明申请
    Sigma ligands for neuronal regeneration and functional recovery 审中-公开
    Sigma配体用于神经元再生和功能恢复

    公开(公告)号：US20050020483A1

    公开(公告)日：2005-01-27

    申请号：US10868048

    申请日：2004-06-14

    申请人： Donna Oksenberg ,  Mattias Rickhag ,  Mehrdad Shamloo ,  Karoly Nikolich ,  Roman Urfer ,  Tadeusz Wieloch

    发明人： Donna Oksenberg ,  Mattias Rickhag ,  Mehrdad Shamloo ,  Karoly Nikolich ,  Roman Urfer ,  Tadeusz Wieloch

    IPC分类号： A61K31/00 ,  A61K31/195 ,  A61K31/438 ,  A61K31/473 ,  A61K31/485 ,  A61K31/495 ,  A61K38/17 ,  C07D295/096 ,  G06F21/00 ,  H04L29/06

    CPC分类号： C07D295/096 ,  A61K31/00 ,  A61K31/438 ,  A61K31/495

    摘要： The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptors. These molecules can be delivered alone or in combination with agents which treat or prevent neurodegenerative diseases such as those caused by ischemic stroke, diabetic peripheral neuropathy, cancer therapy induced neuropathy, multiple sclerosis, amyotrophic lateral sclerosis, traumatic brain injury, spinal cord injury, Huntington's disease or Parkinson's disease. In other methods, the sigma receptor ligands are administered after stroke to facilitate functional recovery. The administration of the sigma receptor ligands effects faster functional recovery.

    摘要翻译： 本发明公开了用于促进神经退行性疾病中的神经元再生和功能恢复的方法和组合物。 该方法和组合物利用了σ受体的配体。 这些分子可以单独递送或与治疗或预防神经变性疾病如由缺血性卒中，糖尿病性周围神经病变，癌症治疗诱发的神经病变，多发性硬化，肌萎缩性侧索硬化，创伤性脑损伤，脊髓损伤，亨廷顿舞蹈症 疾病或帕金森病。 在其他方法中，σ受体配体在中风后施用以促进功能恢复。 σ受体配体的施用使功能恢复更快。

    METHODS FOR INHIBITING DYRK1A TO TREAT CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
    6.
    发明申请
    METHODS FOR INHIBITING DYRK1A TO TREAT CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS 审中-公开
    抑制DYRK1A治疗中枢神经系统疾病和疾病的方法

    公开(公告)号：US20110136844A1

    公开(公告)日：2011-06-09

    申请号：US12884480

    申请日：2010-09-17

    申请人： Irina Shcherbakova ,  Karoly Nikolich

    发明人： Irina Shcherbakova ,  Karoly Nikolich

    IPC分类号： A61K31/438 ,  A61K31/437 ,  A61P25/28 ,  A61P25/16 ,  A61P25/00 ,  A61P25/22 ,  A61P25/18

    CPC分类号： A61K31/437 ,  A61K31/438

    摘要： Compositions and methods for treating, preventing and/or delaying the onset and/or the development of diseases and disorders of the central nervous system are disclosed. The present disclosure relates to indoloquinoline compounds that are capable of inhibiting at least one protein kinase, and to methods for preparing and uses of such compounds. The compounds described herein are administered to patients to achieve a therapeutic effect.

    摘要翻译： 公开了用于治疗，预防和/或延缓中枢神经系统疾病和病症发作和/或发展的组合物和方法。 本公开涉及能够抑制至少一种蛋白激酶的吲哚喹啉化合物，以及这些化合物的制备和用途的方法。 将本文所述的化合物施用于患者以实现治疗效果。

    IGF-1 to improve neural outcome
    8.
    再颁专利
    IGF-1 to improve neural outcome 有权
    IGF-1改善神经结局

    公开(公告)号：USRE43982E1

    公开(公告)日：2013-02-05

    申请号：US10606745

    申请日：2003-06-27

    申请人： Peter Gluckman ,  Karoly Nikolich

    发明人： Peter Gluckman ,  Karoly Nikolich

    IPC分类号： A61K38/30

    摘要： A method of treating injuries to or diseases of the central nervous system that predominantly effects glia and/or non-cholinergic neuronal cells characterized in that it comprises the step of increasing the active concentration(s) of insulin-like growth factor 1 and/or analogues thereof in the central nervous system of the patient. The present invention also provides therapeutic compositions comprising insulin-like growth factor 1 and/or analogues thereof for administration to a patient at or following a neural insult, which compositions are useful in minimizing damage to the central nervous system that would otherwise occur following the insult.

    摘要翻译： 治疗主要影响神经胶质细胞和/或非胆碱能神经细胞的中枢神经系统的损伤或疾病的方法，其特征在于其包括增加胰岛素样生长因子1和/或 在患者的中枢神经系统中的类似物。 本发明还提供包含胰岛素样生长因子1和/或其类似物的治疗组合物，用于在神经损伤或神经损伤时向患者施用，所述组合物可用于最小化在侮辱之后发生的对中枢神经系统的损伤 。